GCM
TEVA icon

Greenland Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Greenland Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,000
Closed -$551K – 429
2024
Q4 		$551K Buy
+25,000
New +$455K 0.09% 182

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Greenland Capital Management's TEVA Position: Q1 2026 in Review

Greenland Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 5.3% in Q1 2026, selling an estimated $193K and leaving 107,500 shares worth $3.24M. The position accounts for 0.41% of the portfolio, ranked #53.

Greenland Capital Management first reported a position in TEVA in Q4 2024 and has held it in 4 quarters since. The position peaked at $3.54M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Greenland Capital Management held 107,500 shares of Teva Pharmaceuticals worth $3.24M as of Q1 2026.
  • Greenland Capital Management sold 6,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $193K.
  • Teva Pharmaceuticals made up 0.41% of Greenland Capital Management's portfolio in Q1 2026, its #53 holding.
  • Greenland Capital Management first reported a position in Teva Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Greenland Capital Management's Teva Pharmaceuticals position peaked at $3.54M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Greenland Capital Management's 13F filing for Q1 2026, filed 15 May 2026.